Q-omics provides the consensus-scored ACTBP15 profile across patient tissues and cancer cell-line models. ACTBP15 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ACTBP15 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, ACTBP15 RNA expression shows 15,365 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, HNSC, and THYM as cancer lineages where ACTBP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ACTBP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ACTBP15 survival associations across molecular data types. ACTBP15 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ACTBP15 RNA expression–survival associations across cancer types. High ACTBP15 expression shows unfavorable associations in ACC, BRCA, LGG and UVM, but favorable associations in UCS and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ACTBP15 RNA expression.
This table summarizes ACTBP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ACTBP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ACTBP15 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, COAD, CHOL and BRCA. The HNSC box plot shows higher ACTBP15 RNA expression in tumor versus normal tissue (log2 FC = +0.215, t-test p < 0.001).
This table shows molecular features associated with ACTBP15 in patient tissues and cancer cell lines. In patient samples, ACTBP15 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
